{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T03:03:25Z","timestamp":1743044605261,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":216,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781461485193"},{"type":"electronic","value":"9781461485209"}],"license":[{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-1-4614-8520-9_14","type":"book-chapter","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T21:01:25Z","timestamp":1380142885000},"page":"159-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Treatment Complications and Supportive Care"],"prefix":"10.1007","author":[{"given":"Francis","family":"Buadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asher Chanan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,4]]},"reference":[{"issue":"25","key":"14_CR00141","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582\u201390.","journal-title":"N Engl J Med"},{"issue":"6","key":"14_CR00142","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.hoc.2007.08.006","volume":"21","author":"J Blade","year":"2007","unstructured":"Blade J, Rosinol L. Complications of multiple myeloma. Hematol Oncol Clin North Am. 2007;21(6):1231\u201346.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"14_CR00143","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4067\/S0034-98872007000900003","volume":"135","author":"LG Conte","year":"2007","unstructured":"Conte LG, et al. Clinical features and survival of Chilean patients with multiple myeloma. Rev Med Chil. 2007;135(9):1111\u20137.","journal-title":"Rev Med Chil"},{"issue":"5","key":"14_CR00144","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749\u201357.","journal-title":"Br J Haematol"},{"issue":"1","key":"14_CR00145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333.","journal-title":"Mayo Clin Proc"},{"issue":"36","key":"14_CR00146","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219\u201326.","journal-title":"J Clin Oncol"},{"issue":"21","key":"14_CR00147","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","volume":"310","author":"B Barlogie","year":"1984","unstructured":"Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310(21):1353\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"14_CR00148","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","volume":"33","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33(2):86\u20139.","journal-title":"Am J Hematol"},{"issue":"11","key":"14_CR00149","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1080\/10428190600908620","volume":"47","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Kastritis E. Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy? Leuk Lymphoma. 2006;47(11):2271\u20132.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"14_CR001410","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","volume":"9","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009;9(4):278\u201388.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"14_CR001411","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14_CR001412","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29\u201337.","journal-title":"Lancet Oncol"},{"issue":"10","key":"14_CR001413","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","volume":"110","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10): 3557\u201360.","journal-title":"Blood"},{"issue":"11","key":"14_CR001414","first-page":"1498","volume":"91","author":"JL Harousseau","year":"2006","unstructured":"Harousseau JL, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91(11):1498\u2013505.","journal-title":"Haematologica"},{"issue":"11","key":"14_CR001415","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","volume":"121","author":"X Leleu","year":"2013","unstructured":"Leleu X, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood. 2013;121(11):1968\u201375.","journal-title":"Blood"},{"issue":"30","key":"14_CR001416","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","volume":"27","author":"MQ Lacy","year":"2009","unstructured":"Lacy MQ, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008\u201314.","journal-title":"J Clin Oncol"},{"issue":"11","key":"14_CR001417","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","volume":"24","author":"MQ Lacy","year":"2010","unstructured":"Lacy MQ, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24(11):1934\u20139.","journal-title":"Leukemia"},{"issue":"11","key":"14_CR001418","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","volume":"118","author":"MQ Lacy","year":"2011","unstructured":"Lacy MQ, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011; 118(11):2970\u20135.","journal-title":"Blood"},{"issue":"14","key":"14_CR001419","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817\u201325.","journal-title":"Blood"},{"issue":"24","key":"14_CR001420","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","volume":"119","author":"R Vij","year":"2012","unstructured":"Vij R, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma. Blood. 2012;119(24): 5661\u201370.","journal-title":"Blood"},{"issue":"5","key":"14_CR001421","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516\u201320.","journal-title":"Blood"},{"issue":"16","key":"14_CR001422","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655\u201364.","journal-title":"N Engl J Med"},{"issue":"2","key":"14_CR001423","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1634\/theoncologist.2010-0154","volume":"16","author":"D Castellano","year":"2011","unstructured":"Castellano D, et al. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16(2):136\u201345.","journal-title":"Oncologist"},{"issue":"1","key":"14_CR001424","first-page":"12","volume":"17","author":"GT Elliott","year":"1983","unstructured":"Elliott GT, McKenzie MW. Treatment of hypercalcemia. Drug Intell Clin Pharm. 1983;17(1):12\u201322.","journal-title":"Drug Intell Clin Pharm"},{"issue":"3","key":"14_CR001425","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archinte.1991.00400030039007","volume":"151","author":"FR Singer","year":"1991","unstructured":"Singer FR, et al. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch Intern Med. 1991;151(3):471\u20136.","journal-title":"Arch Intern Med"},{"issue":"4","key":"14_CR001426","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/00365599309182276","volume":"27","author":"A Davenport","year":"1993","unstructured":"Davenport A, Goel S, Mackenzie JC. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol. 1993;27(4):447\u201351.","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"14_CR001427","first-page":"175","volume":"45","author":"CE Machado","year":"1996","unstructured":"Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol. 1996;45(3):175\u20139.","journal-title":"Clin Nephrol"},{"issue":"17","key":"14_CR001428","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/archinte.1994.00420170079008","volume":"154","author":"R Gucalp","year":"1994","unstructured":"Gucalp R, et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med. 1994;154(17):1935\u201344.","journal-title":"Arch Intern Med"},{"issue":"3","key":"14_CR001429","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(93)90282-T","volume":"95","author":"SR Nussbaum","year":"1993","unstructured":"Nussbaum SR, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993;95(3):297\u2013304.","journal-title":"Am J Med"},{"issue":"2 Suppl 6","key":"14_CR001430","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0093-7754(01)90261-1","volume":"28","author":"PP Major","year":"2001","unstructured":"Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol. 2001;28(2 Suppl 6):17\u201324.","journal-title":"Semin Oncol"},{"issue":"1","key":"14_CR001431","first-page":"197","volume":"5","author":"M Sekine","year":"1998","unstructured":"Sekine M, Takami H. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia. Oncol Rep. 1998;5(1):197\u20139.","journal-title":"Oncol Rep"},{"issue":"2","key":"14_CR001432","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7326\/0003-4819-93-2-269","volume":"93","author":"ML Binstock","year":"1980","unstructured":"Binstock ML, Mundy GR. Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med. 1980;93(2): 269\u201372.","journal-title":"Ann Intern Med"},{"issue":"2","key":"14_CR001433","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/cpt1978242219","volume":"24","author":"LA Wisneski","year":"1978","unstructured":"Wisneski LA, et al. Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther. 1978;24(2):219\u201322.","journal-title":"Clin Pharmacol Ther"},{"issue":"29","key":"14_CR001434","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1200\/JCO.2012.41.7923","volume":"30","author":"SA Boikos","year":"2012","unstructured":"Boikos SA, Hammers HJ. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia. J Clin Oncol. 2012;30(29):e299.","journal-title":"J Clin Oncol"},{"issue":"12","key":"14_CR001435","doi-asserted-by":"crossref","first-page":"906","DOI":"10.7326\/0003-4819-156-12-201206190-00026","volume":"156","author":"A Bech","year":"2012","unstructured":"Bech A, de Boer H. Denosumab for tumor-induced hypercalcemia complicated by renal failure. Ann Intern Med. 2012;156(12):906\u20137.","journal-title":"Ann Intern Med"},{"issue":"3","key":"14_CR001436","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","volume":"25","author":"JJ Body","year":"2010","unstructured":"Body JJ, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res. 2010;25(3):440\u20136.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"14_CR001437","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0609.2000.90074.x","volume":"64","author":"N Abildgaard","year":"2000","unstructured":"Abildgaard N, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol. 2000;64(2):121\u20139.","journal-title":"Eur J Haematol"},{"issue":"4","key":"14_CR001438","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2141.1990.tb06330.x","volume":"74","author":"A Carter","year":"1990","unstructured":"Carter A, et al. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol. 1990;74(4):424\u201331.","journal-title":"Br J Haematol"},{"issue":"1","key":"14_CR001439","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2249.1993.tb05943.x","volume":"92","author":"F Merico","year":"1993","unstructured":"Merico F, et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol. 1993;92(1):27\u201331.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"14_CR001440","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","volume":"25","author":"R Walker","year":"2007","unstructured":"Walker R, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25(9):1121\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14_CR001441","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3324\/haematol.2012.066555","volume":"98","author":"S Waheed","year":"2013","unstructured":"Waheed S, et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica. 2013;98(1):71\u20138.","journal-title":"Haematologica"},{"issue":"10","key":"14_CR001442","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068\u201376.","journal-title":"Blood"},{"issue":"1","key":"14_CR001443","first-page":"43","volume":"11","author":"MP Yaneva","year":"2006","unstructured":"Yaneva MP, Goranova-Marinova V, Goranov S. Palliative radiotherapy in patients with multiple myeloma. J BUON. 2006;11(1):43\u20138.","journal-title":"J BUON"},{"issue":"2","key":"14_CR001444","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-8140(91)90144-6","volume":"20","author":"IA Adamietz","year":"1991","unstructured":"Adamietz IA, et al. Palliative radiotherapy in plasma cell myeloma. Radiother Oncol. 1991;20(2):111\u20136.","journal-title":"Radiother Oncol"},{"issue":"5","key":"14_CR001445","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0360-3016(93)90308-I","volume":"25","author":"BR Leigh","year":"1993","unstructured":"Leigh BR, et al. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys. 1993;25(5):801\u20134.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"14_CR001446","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/1097-0142(19800215)45:4<647::AID-CNCR2820450405>3.0.CO;2-E","volume":"45","author":"WB Mill","year":"1980","unstructured":"Mill WB, Griffith R. The role of radiation therapy in the management of plasma cell tumors. Cancer. 1980;45(4):647\u201352.","journal-title":"Cancer"},{"issue":"3","key":"14_CR001447","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1148\/radiol.09081698","volume":"254","author":"G Saliou","year":"2010","unstructured":"Saliou G, et al. Percutaneous vertebroplasty for pain management in malignant fractures of the spine with epidural involvement. Radiology. 2010;254(3):882\u201390.","journal-title":"Radiology"},{"issue":"6","key":"14_CR001448","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3340\/jkns.2009.45.6.369","volume":"45","author":"BS Lim","year":"2009","unstructured":"Lim BS, Chang UK, Youn SM. Clinical outcomes after percutaneous vertebroplasty for pathologic compression fractures in osteolytic metastatic spinal disease. J Korean Neurosurg Soc. 2009;45(6):369\u201374.","journal-title":"J Korean Neurosurg Soc"},{"issue":"2","key":"14_CR001449","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0609.2005.00573.x","volume":"76","author":"B Bartolozzi","year":"2006","unstructured":"Bartolozzi B, et al. Percutaneous vertebroplasty and kyphoplasty in patients with multiple myeloma. Eur J Haematol. 2006;76(2):180\u20131.","journal-title":"Eur J Haematol"},{"issue":"4","key":"14_CR001450","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2004.04809.x","volume":"124","author":"TH Diamond","year":"2004","unstructured":"Diamond TH, et al. Percutaneous vertebroplasty for acute vertebral body fracture and deformity in multiple myeloma: a short report. Br J Haematol. 2004;124(4):485\u20137.","journal-title":"Br J Haematol"},{"issue":"3","key":"14_CR001451","first-page":"555","volume":"28","author":"MH Voormolen","year":"2007","unstructured":"Voormolen MH, et al. Percutaneous vertebroplasty compared with optimal pain medication treatment: short-term clinical outcome of patients with subacute or chronic painful osteoporotic vertebral compression fractures. The VERTOS study. AJNR Am J Neuroradiol. 2007;28(3):555\u201360.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"9668","key":"14_CR001452","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(09)60010-6","volume":"373","author":"D Wardlaw","year":"2009","unstructured":"Wardlaw D, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet. 2009;373(9668):1016\u201324.","journal-title":"Lancet"},{"issue":"6","key":"14_CR001453","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJMoa0900429","volume":"361","author":"R Buchbinder","year":"2009","unstructured":"Buchbinder R, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009;361(6):557\u201368.","journal-title":"N Engl J Med"},{"key":"14_CR001454","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1471-2474-8-126","volume":"8","author":"LA Gray","year":"2007","unstructured":"Gray LA, et al. INvestigational Vertebroplasty Efficacy and Safety Trial (INVEST): a randomized controlled trial of percutaneous vertebroplasty. BMC Musculoskelet Disord. 2007;8:126.","journal-title":"BMC Musculoskelet Disord"},{"key":"14_CR001455","doi-asserted-by":"crossref","unstructured":"Comstock BA, et al. Investigational Vertebroplasty Safety and Efficacy Trial (INVEST): patient-reported outcomes through 1 year. Radiology. 2013.","DOI":"10.1148\/radiol.13120821"},{"issue":"8","key":"14_CR001456","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488\u201393.","journal-title":"N Engl J Med"},{"issue":"5","key":"14_CR001457","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377\u201387.","journal-title":"Cancer J"},{"issue":"6","key":"14_CR001458","first-page":"478","volume":"59","author":"M Kraj","year":"2002","unstructured":"Kraj M, et al. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Acta Pol Pharm. 2002;59(6):478\u201382.","journal-title":"Acta Pol Pharm"},{"issue":"7","key":"14_CR001459","first-page":"2394","volume":"9","author":"A Ibrahim","year":"2003","unstructured":"Ibrahim A, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003;9(7):2394\u20139.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"14_CR001460","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson JR, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2):593\u2013602.","journal-title":"J Clin Oncol"},{"issue":"9757","key":"14_CR001461","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan GJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989\u201399.","journal-title":"Lancet"},{"issue":"2","key":"14_CR001462","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2009.03581.x","volume":"72","author":"CV Odvina","year":"2009","unstructured":"Odvina CV, et al. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf). 2009;72(2):161\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"14_CR001463","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00198-009-1012-0","volume":"21","author":"N Napoli","year":"2010","unstructured":"Napoli N, Novack D, Armamento-Villareal R. Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. Osteoporos Int. 2010;21(4):705\u20138.","journal-title":"Osteoporos Int"},{"issue":"2","key":"14_CR001464","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/BOT.0b013e3181b6499b","volume":"24","author":"JS Koh","year":"2010","unstructured":"Koh JS, et al. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma. 2010;24(2):75\u201381.","journal-title":"J Orthop Trauma"},{"issue":"8","key":"14_CR001465","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","volume":"81","author":"MQ Lacy","year":"2006","unstructured":"Lacy MQ, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81(8):1047\u201353.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"14_CR001466","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527\u201334.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"14_CR001467","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"BG Durie","year":"2005","unstructured":"Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353(1):99\u2013102; discussion 99\u2013102.","journal-title":"N Engl J Med"},{"issue":"36","key":"14_CR001468","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","volume":"26","author":"A Badros","year":"2008","unstructured":"Badros A, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26(36):5904\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"14_CR001469","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/ajh.21553","volume":"84","author":"S Pozzi","year":"2009","unstructured":"Pozzi S, et al. Bisphosphonates-associated osteonecrosis of the jaw: a long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. Am J Hematol. 2009;84(12): 850\u20132.","journal-title":"Am J Hematol"},{"issue":"4","key":"14_CR001470","first-page":"E336","volume":"12","author":"J Bagan","year":"2007","unstructured":"Bagan J, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12(4):E336\u201340.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"5","key":"14_CR001471","first-page":"9","volume":"39","author":"V Chu","year":"2008","unstructured":"Chu V. Management of patients on bisphosphonates and prevention of bisphosphonate-related osteonecrosis of the jaw. Hawaii Dent J. 2008;39(5):9\u201312; quiz 17.","journal-title":"Hawaii Dent J"},{"issue":"7576","key":"14_CR001472","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/bmj.39024.647558.BE","volume":"333","author":"BN Landis","year":"2006","unstructured":"Landis BN, et al. Osteonecrosis of the jaw after treatment with bisphosphonates: is irreversible, so the focus must be on prevention. BMJ. 2006;333(7576): 982\u20133.","journal-title":"BMJ"},{"issue":"11","key":"14_CR001473","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","volume":"49","author":"V Montefusco","year":"2008","unstructured":"Montefusco V, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008;49(11):2156\u201362.","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"14_CR001474","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082\u201392.","journal-title":"Eur J Cancer"},{"issue":"9","key":"14_CR001475","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125\u201332.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14_CR001476","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007; 48(2):337\u201341.","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"14_CR001477","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blade","year":"1998","unstructured":"Blade J, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158(17):1889\u201393.","journal-title":"Arch Intern Med"},{"issue":"11","key":"14_CR001478","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ki.2008.108","volume":"73","author":"N Leung","year":"2008","unstructured":"Leung N, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73(11):1282\u20138.","journal-title":"Kidney Int"},{"issue":"6","key":"14_CR001479","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980\u20137.","journal-title":"Haematologica"},{"issue":"3","key":"14_CR001480","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","volume":"65","author":"LM Knudsen","year":"2000","unstructured":"Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65(3):175\u201381.","journal-title":"Eur J Haematol"},{"issue":"4","key":"14_CR001481","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3324\/haematol.10759","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92(4):546\u20139.","journal-title":"Haematologica"},{"issue":"6","key":"14_CR001482","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","volume":"59","author":"SH Nasr","year":"2012","unstructured":"Nasr SH, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012;59(6): 786\u201394.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"14_CR001483","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","volume":"143","author":"WF Clark","year":"2005","unstructured":"Clark WF, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"4","key":"14_CR001484","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1990.00390160111022","volume":"150","author":"WJ Johnson","year":"1990","unstructured":"Johnson WJ, et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990;150(4):863\u20139.","journal-title":"Arch Intern Med"},{"issue":"6","key":"14_CR001485","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/ki.1988.127","volume":"33","author":"P Zucchelli","year":"1988","unstructured":"Zucchelli P, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988;33(6):1175\u201380.","journal-title":"Kidney Int"},{"issue":"24","key":"14_CR001486","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMc1101834","volume":"364","author":"BL Burnette","year":"2011","unstructured":"Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011;364(24):2365\u20136.","journal-title":"N Engl J Med"},{"issue":"13","key":"14_CR001487","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","volume":"26","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26(13):2171\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"14_CR001488","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","volume":"129","author":"S Jagannath","year":"2005","unstructured":"Jagannath S, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129(6):776\u201383.","journal-title":"Br J Haematol"},{"issue":"9","key":"14_CR001489","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801\u20139.","journal-title":"Blood"},{"issue":"5","key":"14_CR001490","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrclinonc.2010.31","volume":"7","author":"H Ludwig","year":"2010","unstructured":"Ludwig H, Zojer N. Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nat Rev Clin Oncol. 2010;7(5):289\u201394.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"14_CR001491","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01542.x","volume":"85","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, et al. Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010;85(1):1\u20135.","journal-title":"Eur J Haematol"},{"issue":"2","key":"14_CR001492","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","volume":"73","author":"P Tosi","year":"2004","unstructured":"Tosi P, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73(2):98\u2013103.","journal-title":"Eur J Haematol"},{"issue":"5","key":"14_CR001493","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1080\/10428190801930506","volume":"49","author":"M Roussou","year":"2008","unstructured":"Roussou M, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma. 2008;49(5):890\u20135.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"14_CR001494","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05366.x","volume":"128","author":"K Carlson","year":"2005","unstructured":"Carlson K, Hjorth M, Knudsen LM. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure\u2014a retrospective analysis and recommendations for dose adjustment. Br J Haematol. 2005;128(5):631\u20135.","journal-title":"Br J Haematol"},{"key":"14_CR001495","doi-asserted-by":"crossref","unstructured":"Badros AZ, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013.","DOI":"10.1038\/leu.2013.29"},{"issue":"6","key":"14_CR001496","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","volume":"103","author":"S Jagannath","year":"2005","unstructured":"Jagannath S, et al. Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005;103(6):1195\u2013200.","journal-title":"Cancer"},{"issue":"10","key":"14_CR001497","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3324\/haematol.11463","volume":"92","author":"H Ludwig","year":"2007","unstructured":"Ludwig H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92(10):1411\u20134.","journal-title":"Haematologica"},{"issue":"6","key":"14_CR001498","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","volume":"109","author":"AA Chanan-Khan","year":"2007","unstructured":"Chanan-Khan AA, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109(6):2604\u20136.","journal-title":"Blood"},{"issue":"7","key":"14_CR001499","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.bmt.1703713","volume":"30","author":"S Tauro","year":"2002","unstructured":"Tauro S, et al. Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant. 2002;30(7):471\u20133.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"14_CR0014100","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822\u20139.","journal-title":"Br J Haematol"},{"issue":"8","key":"14_CR0014101","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","volume":"33","author":"CK Lee","year":"2004","unstructured":"Lee CK, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33(8):823\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"14_CR0014102","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.1997.tb01677.x","volume":"58","author":"P Musto","year":"1997","unstructured":"Musto P, et al. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Haematol. 1997;58(5):314\u20139.","journal-title":"Eur J Haematol"},{"issue":"3","key":"14_CR0014103","first-page":"262","volume":"79","author":"G Vaiopoulos","year":"1994","unstructured":"Vaiopoulos G, et al. Multiple myeloma associated with autoimmune hemolytic anemia. Haematologica. 1994;79(3):262\u20134.","journal-title":"Haematologica"},{"issue":"12","key":"14_CR0014104","first-page":"469","volume":"62","author":"M Friedland","year":"1979","unstructured":"Friedland M, Schaefer P. Myelomatosis and hemolytic anemia. Hemolytic anemia, a rare complication of multiple myeloma, is successfully managed by splenectomy. R I Med J. 1979;62(12):469\u201371.","journal-title":"R I Med J"},{"issue":"7","key":"14_CR0014105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2169\/internalmedicine.43.595","volume":"43","author":"H Wada","year":"2004","unstructured":"Wada H, et al. Multiple myeloma complicated by autoimmune hemolytic anemia. Intern Med. 2004;43(7):595\u20138.","journal-title":"Intern Med"},{"issue":"19","key":"14_CR0014106","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375\u201382.","journal-title":"Blood"},{"issue":"7","key":"14_CR0014107","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","volume":"115","author":"F Gay","year":"2010","unstructured":"Gay F, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010;115(7):1343\u201350.","journal-title":"Blood"},{"issue":"8","key":"14_CR0014108","first-page":"249","volume":"61","author":"LT Vlasveld","year":"2003","unstructured":"Vlasveld LT. Low cobalamin (vitamin B12) levels in multiple myeloma: a retrospective study. Neth J Med. 2003;61(8):249\u201352.","journal-title":"Neth J Med"},{"issue":"29","key":"14_CR0014109","first-page":"4321","volume":"119","author":"F Heyerdahl","year":"1999","unstructured":"Heyerdahl F, Kildahl-Andersen O. Myelomatosis and low level of vitamin B12. Tidsskr Nor Laegeforen. 1999;119(29):4321\u20132.","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"1","key":"14_CR0014110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00000441-197801000-00011","volume":"275","author":"PE Perillie","year":"1978","unstructured":"Perillie PE. Myeloma and pernicious anemia. Am J Med Sci. 1978;275(1):93\u20138.","journal-title":"Am J Med Sci"},{"issue":"4","key":"14_CR0014111","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1600-0609.1978.tb02468.x","volume":"20","author":"OP Hansen","year":"1978","unstructured":"Hansen OP, et al. Interrelationships between Vitamin B12 and folic acid in myelomatosis: cobalamin coenzyme and tetrahydrofolic acid function. Scand J Haematol. 1978;20(4):360\u201370.","journal-title":"Scand J Haematol"},{"issue":"24","key":"14_CR0014112","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","volume":"322","author":"H Ludwig","year":"1990","unstructured":"Ludwig H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990;322(24):1693\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"14_CR0014113","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","volume":"20","author":"A Osterborg","year":"2002","unstructured":"Osterborg A, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol. 2002;20(10):2486\u201394.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14_CR0014114","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","volume":"113","author":"F Dammacco","year":"2001","unstructured":"Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113(1):172\u20139.","journal-title":"Br J Haematol"},{"issue":"19","key":"14_CR0014115","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","volume":"155","author":"JP Garton","year":"1995","unstructured":"Garton JP, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med. 1995;155(19):2069\u201374.","journal-title":"Arch Intern Med"},{"issue":"12","key":"14_CR0014116","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","volume":"86","author":"M Cazzola","year":"1995","unstructured":"Cazzola M, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin\u2019s lymphoma: dose finding and identification of predictors of response. Blood. 1995; 86(12):4446\u201353.","journal-title":"Blood"},{"issue":"1","key":"14_CR0014117","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","volume":"26","author":"JD Rizzo","year":"2008","unstructured":"Rizzo JD, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26(1):132\u201349.","journal-title":"J Clin Oncol"},{"issue":"8","key":"14_CR0014118","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/cncr.22221","volume":"107","author":"DJ Straus","year":"2006","unstructured":"Straus DJ, et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 2006;107(8):1909\u201317.","journal-title":"Cancer"},{"issue":"10","key":"14_CR0014119","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1634\/theoncologist.12-10-1253","volume":"12","author":"V Charu","year":"2007","unstructured":"Charu V, et al. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007;12(10):1253\u201363.","journal-title":"Oncologist"},{"issue":"7","key":"14_CR0014120","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","volume":"87","author":"A Osterborg","year":"1996","unstructured":"Osterborg A, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin\u2019s lymphoma\u2014a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin\u2019s Lymphoma. Blood. 1996;87(7):2675\u201382.","journal-title":"Blood"},{"issue":"8","key":"14_CR0014121","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","volume":"299","author":"CL Bennett","year":"2008","unstructured":"Bennett CL, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8): 914\u201324.","journal-title":"JAMA"},{"issue":"6","key":"14_CR0014122","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1046\/j.1523-1755.2002.00657.x","volume":"62","author":"Y Vanrenterghem","year":"2002","unstructured":"Vanrenterghem Y, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002;62(6):2167\u201375.","journal-title":"Kidney Int"},{"issue":"1","key":"14_CR0014123","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2141.2003.04252.x","volume":"121","author":"M Steurer","year":"2003","unstructured":"Steurer M, et al. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol. 2003;121(1):101\u20133.","journal-title":"Br J Haematol"},{"issue":"20","key":"14_CR0014124","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085\u201398.","journal-title":"N Engl J Med"},{"issue":"5720","key":"14_CR0014125","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/bmj.3.5720.438","volume":"3","author":"D Catovsky","year":"1970","unstructured":"Catovsky D, et al. Thromboembolic complications in myelomatosis. Br Med J. 1970;3(5720):438\u20139.","journal-title":"Br Med J"},{"issue":"9","key":"14_CR0014126","first-page":"1141","volume":"89","author":"M Galli","year":"2004","unstructured":"Galli M, et al. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica. 2004;89(9):1141\u20132.","journal-title":"Haematologica"},{"issue":"7","key":"14_CR0014127","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/00007611-198807000-00012","volume":"81","author":"KB Doughney","year":"1988","unstructured":"Doughney KB, Williams DM, Penn RL. Multiple myeloma: infectious complications. South Med J. 1988;81(7):855\u20138.","journal-title":"South Med J"},{"issue":"2","key":"14_CR0014128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0891-5520(05)70151-3","volume":"15","author":"F Paradisi","year":"2001","unstructured":"Paradisi F, Corti G, Cinelli R. Infections in multiple myeloma. Infect Dis Clin North Am. 2001;15(2):373\u201384; vii\u2013viii.","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"14_CR0014129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/00365548409087137","volume":"16","author":"F Espersen","year":"1984","unstructured":"Espersen F, et al. Current patterns of bacterial infection in myelomatosis. Scand J Infect Dis. 1984;16(2):169\u201373.","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"14_CR0014130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.1983.tb01521.x","volume":"31","author":"G Hopen","year":"1983","unstructured":"Hopen G, et al. Granulocyte function in malignant monoclonal gammopathy. Scand J Haematol. 1983;31(2):133\u201343.","journal-title":"Scand J Haematol"},{"issue":"3","key":"14_CR0014131","first-page":"282","volume":"13","author":"DR Jacobson","year":"1986","unstructured":"Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol. 1986;13(3):282\u201390.","journal-title":"Semin Oncol"},{"issue":"9","key":"14_CR0014132","first-page":"1022","volume":"88","author":"C Cesana","year":"2003","unstructured":"Cesana C, et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica. 2003;88(9):1022\u20138.","journal-title":"Haematologica"},{"issue":"4","key":"14_CR0014133","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood.V55.4.602.602","volume":"55","author":"BD Cheson","year":"1980","unstructured":"Cheson BD, Plass RR, Rothstein G. Defective opsonization in multiple myeloma. Blood. 1980;55(4): 602\u20136.","journal-title":"Blood"},{"issue":"3","key":"14_CR0014134","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","volume":"48","author":"RM Hargreaves","year":"1995","unstructured":"Hargreaves RM, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol. 1995;48(3):260\u20136.","journal-title":"J Clin Pathol"},{"issue":"6","key":"14_CR0014135","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9343(81)90303-X","volume":"71","author":"RT Perri","year":"1981","unstructured":"Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med. 1981;71(6):935\u201340.","journal-title":"Am J Med"},{"issue":"1","key":"14_CR0014136","first-page":"41","volume":"36","author":"S Goranov","year":"1994","unstructured":"Goranov S. Clinical problems of infectious complications in patients with multiple myeloma. Folia Med (Plovdiv). 1994;36(1):41\u20136.","journal-title":"Folia Med (Plovdiv)"},{"issue":"1","key":"14_CR0014137","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-96-1-47","volume":"96","author":"DG Savage","year":"1982","unstructured":"Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med. 1982;96(1):47\u201350.","journal-title":"Ann Intern Med"},{"issue":"2","key":"14_CR0014138","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000225611","volume":"39","author":"BS Shaikh","year":"1982","unstructured":"Shaikh BS, et al. Changing patterns of infections in patients with multiple myeloma. Oncology. 1982;39(2):78\u201382.","journal-title":"Oncology"},{"issue":"1","key":"14_CR0014139","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21(1):16\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"14_CR0014140","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLM.2008.n.031","volume":"8","author":"SJ Kim","year":"2008","unstructured":"Kim SJ, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma. 2008;8(4): 237\u201340.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"6","key":"14_CR0014141","first-page":"488","volume":"50","author":"Y Hasegawa","year":"2009","unstructured":"Hasegawa Y, et al. Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy. Rinsho Ketsueki. 2009;50(6):488\u201394.","journal-title":"Rinsho Ketsueki"},{"issue":"10","key":"14_CR0014142","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.4049\/jimmunol.0901596","volume":"183","author":"M Basler","year":"2009","unstructured":"Basler M, et al. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009;183(10):6145\u201350.","journal-title":"J Immunol"},{"issue":"29","key":"14_CR0014143","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","volume":"26","author":"A Chanan-Khan","year":"2008","unstructured":"Chanan-Khan A, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26(29): 4784\u201390.","journal-title":"J Clin Oncol"},{"issue":"5","key":"14_CR0014144","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","volume":"12","author":"S Jagannath","year":"2012","unstructured":"Jagannath S, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12(5):310\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"14_CR0014145","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","volume":"158","author":"R Vij","year":"2012","unstructured":"Vij R, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012;158(6):739\u201348.","journal-title":"Br J Haematol"},{"issue":"8","key":"14_CR0014146","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1086\/428732","volume":"40","author":"S Reuter","year":"2005","unstructured":"Reuter S, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005;40(8):1087\u201393.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"14_CR0014147","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","volume":"100","author":"MM Oken","year":"1996","unstructured":"Oken MM, et al. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996;100(6):624\u20138.","journal-title":"Am J Med"},{"issue":"14","key":"14_CR0014148","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","volume":"21","author":"CK Lee","year":"2003","unstructured":"Lee CK, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003;21(14):2732\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"14_CR0014149","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","volume":"23","author":"CB Reeder","year":"2009","unstructured":"Reeder CB, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337\u201341.","journal-title":"Leukemia"},{"issue":"2","key":"14_CR0014150","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF02113579","volume":"25","author":"J van der Lelie","year":"1997","unstructured":"van der Lelie J, et al. Pneumocystis carinii pneumonia in HIV-negative patients with haematologic disease. Infection. 1997;25(2):78\u201381.","journal-title":"Infection"},{"issue":"5","key":"14_CR0014151","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjc.6602412","volume":"92","author":"LJ Worth","year":"2005","unstructured":"Worth LJ, et al. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer. 2005;92(5):867\u201372.","journal-title":"Br J Cancer"},{"issue":"2","key":"14_CR0014152","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.2002.03419.x","volume":"117","author":"L Pagano","year":"2002","unstructured":"Pagano L, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years\u2019 experience of infection in GIMEMA centres. Br J Haematol. 2002;117(2):379\u201386.","journal-title":"Br J Haematol"},{"issue":"1","key":"14_CR0014153","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0002-9343(87)90380-9","volume":"82","author":"SG Peters","year":"1987","unstructured":"Peters SG, Prakash UB. Pneumocystis carinii pneumonia. Review of 53 cases. Am J Med. 1987;82(1):73\u20138.","journal-title":"Am J Med"},{"issue":"1","key":"14_CR0014154","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0163-4453(03)00038-0","volume":"47","author":"F Roblot","year":"2003","unstructured":"Roblot F, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect. 2003;47(1):19\u201327.","journal-title":"J Infect"},{"issue":"1","key":"14_CR0014155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","volume":"71","author":"SH Yale","year":"1996","unstructured":"Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5\u201313.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"14_CR0014156","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","volume":"115","author":"E Vickrey","year":"2009","unstructured":"Vickrey E, et al. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009;115(1):229\u201332.","journal-title":"Cancer"},{"issue":"2","key":"14_CR0014157","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3816\/CLM.2009.n.036","volume":"9","author":"L Pour","year":"2009","unstructured":"Pour L, et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2009;9(2):151\u20133.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"7","key":"14_CR0014158","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","volume":"82","author":"JD Robertson","year":"2000","unstructured":"Robertson JD, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000;82(7):1261\u20135.","journal-title":"Br J Cancer"},{"issue":"9","key":"14_CR0014159","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1469-0691.2005.01221.x","volume":"11","author":"HM Einarsdottir","year":"2005","unstructured":"Einarsdottir HM, et al. Nationwide study of recurrent invasive pneumococcal infections in a population with a low prevalence of human immunodeficiency virus infection. Clin Microbiol Infect. 2005;11(9): 744\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"14_CR0014160","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/1097-0142(19810915)48:6<1377::AID-CNCR2820480620>3.0.CO;2-T","volume":"48","author":"RA Shildt","year":"1981","unstructured":"Shildt RA, et al. Polyvalent pneumococcal immunization of patients with plasma cell dyscrasias. Cancer. 1981;48(6):1377\u201380.","journal-title":"Cancer"},{"issue":"Suppl","key":"14_CR0014161","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1093\/clinids\/3.Supplement_1.S184","volume":"3","author":"SH Landesman","year":"1981","unstructured":"Landesman SH, Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis. 1981;3(Suppl): S184\u201397.","journal-title":"Rev Infect Dis"},{"issue":"3","key":"14_CR0014162","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0002-9343(80)90014-5","volume":"69","author":"HM Lazarus","year":"1980","unstructured":"Lazarus HM, et al. Pneumococcal vaccination: the response of patients with multiple myeloma. Am J Med. 1980;69(3):419\u201323.","journal-title":"Am J Med"},{"issue":"3A","key":"14_CR0014163","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0002-9343(84)90328-0","volume":"76","author":"DS Gordon","year":"1984","unstructured":"Gordon DS, et al. Phase I study of intravenous gamma globulin in multiple myeloma. Am J Med. 1984;76(3A):111\u20136.","journal-title":"Am J Med"},{"issue":"4","key":"14_CR0014164","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2141.1995.tb08447.x","volume":"89","author":"P Musto","year":"1995","unstructured":"Musto P, Brugiatelli M, Carotenuto M. Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma. Br J Haematol. 1995;89(4):945\u20136.","journal-title":"Br J Haematol"},{"issue":"5","key":"14_CR0014165","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","volume":"50","author":"P Raanani","year":"2009","unstructured":"Raanani P, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50(5):764\u201372.","journal-title":"Leuk Lymphoma"},{"issue":"8905","key":"14_CR0014166","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","volume":"343","author":"HM Chapel","year":"1994","unstructured":"Chapel HM, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994;343(8905):1059\u201363.","journal-title":"Lancet"},{"issue":"1","key":"14_CR0014167","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1212\/WNL.31.1.24","volume":"31","author":"JJ Kelly Jr","year":"1981","unstructured":"Kelly Jr JJ, et al. The spectrum of peripheral neuropathy in myeloma. Neurology. 1981;31(1):24\u201331.","journal-title":"Neurology"},{"issue":"21","key":"14_CR0014168","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","volume":"27","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009;27(21):3518\u201325.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14_CR0014169","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1212\/WNL.33.2.202","volume":"33","author":"JJ Kelly Jr","year":"1983","unstructured":"Kelly Jr JJ, et al. Osteosclerotic myeloma and peripheral neuropathy. Neurology. 1983;33(2):202\u201310.","journal-title":"Neurology"},{"issue":"7","key":"14_CR0014170","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","volume":"101","author":"A Dispenzieri","year":"2003","unstructured":"Dispenzieri A, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7): 2496\u2013506.","journal-title":"Blood"},{"issue":"7","key":"14_CR0014171","first-page":"409","volume":"41","author":"JR Wilson","year":"2001","unstructured":"Wilson JR, Stittsworth Jr JD, Fisher MA. Electrodiagnostic patterns in MGUS neuropathy. Electromyogr Clin Neurophysiol. 2001;41(7): 409\u201318.","journal-title":"Electromyogr Clin Neurophysiol"},{"issue":"3","key":"14_CR0014172","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00313731","volume":"228","author":"L Noring","year":"1982","unstructured":"Noring L, et al. Peripheral neuropathy in patients with benign monoclonal gammopathy\u2014a pilot study. J Neurol. 1982;228(3):185\u201394.","journal-title":"J Neurol"},{"issue":"6","key":"14_CR0014173","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0404.1992.tb06033.x","volume":"85","author":"E Nobile-Orazio","year":"1992","unstructured":"Nobile-Orazio E, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand. 1992;85(6):383\u201390.","journal-title":"Acta Neurol Scand"},{"issue":"4511","key":"14_CR0014174","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1126\/science.7268405","volume":"213","author":"UA Besinger","year":"1981","unstructured":"Besinger UA, et al. Myeloma neuropathy: passive transfer from man to mouse. Science. 1981; 213(4511):1027\u201330.","journal-title":"Science"},{"issue":"7","key":"14_CR0014175","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1212\/WNL.34.7.934","volume":"34","author":"RI Roelofs","year":"1984","unstructured":"Roelofs RI, et al. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984;34(7):934\u20138.","journal-title":"Neurology"},{"issue":"8","key":"14_CR0014176","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/1097-0142(19901015)66:8<1697::AID-CNCR2820660808>3.0.CO;2-G","volume":"66","author":"RG van der Hoop","year":"1990","unstructured":"van der Hoop RG, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer. 1990;66(8):1697\u2013702.","journal-title":"Cancer"},{"issue":"1","key":"14_CR0014177","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","volume":"13","author":"AJ Windebank","year":"2008","unstructured":"Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27\u201346.","journal-title":"J Peripher Nerv Syst"},{"issue":"27","key":"14_CR0014178","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","volume":"24","author":"L Mileshkin","year":"2006","unstructured":"Mileshkin L, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24(27):4507\u201314.","journal-title":"J Clin Oncol"},{"issue":"6","key":"14_CR0014179","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","volume":"69","author":"R Plasmati","year":"2007","unstructured":"Plasmati R, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007;69(6):573\u201381.","journal-title":"Neurology"},{"issue":"5","key":"14_CR0014180","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","volume":"112","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593\u20139.","journal-title":"Blood"},{"issue":"6","key":"14_CR0014181","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/0091270009335001","volume":"49","author":"WL Dahut","year":"2009","unstructured":"Dahut WL, et al. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol. 2009;49(6):650\u201360.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"14_CR0014182","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","volume":"108","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108(10):3458\u201364.","journal-title":"Blood"},{"issue":"19","key":"14_CR0014183","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113\u201320.","journal-title":"J Clin Oncol"},{"issue":"24","key":"14_CR0014184","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"6","key":"14_CR0014185","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","volume":"144","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895\u2013903.","journal-title":"Br J Haematol"},{"issue":"5","key":"14_CR0014186","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431\u201340.","journal-title":"Lancet Oncol"},{"issue":"3","key":"14_CR0014187","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3816\/CLM.2008.n.017","volume":"8","author":"J El-Cheikh","year":"2008","unstructured":"El-Cheikh J, et al. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin Lymphoma Myeloma. 2008;8(3):146\u201352.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"14_CR0014188","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cncr.23606","volume":"113","author":"JD Hainsworth","year":"2008","unstructured":"Hainsworth JD, et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer. 2008;113(4):765\u201371.","journal-title":"Cancer"},{"issue":"2","key":"14_CR0014189","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3816\/CLM.2006.n.050","volume":"7","author":"A Suvannasankha","year":"2006","unstructured":"Suvannasankha A, et al. Weekly bortezomib\/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma. 2006;7(2):131\u20134.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"14_CR0014190","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","volume":"110","author":"J Rosenstock","year":"2004","unstructured":"Rosenstock J, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110(3): 628\u201338.","journal-title":"Pain"},{"issue":"2","key":"14_CR0014191","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","volume":"12","author":"T Tolle","year":"2008","unstructured":"Tolle T, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12(2):203\u201313.","journal-title":"Eur J Pain"},{"issue":"4","key":"14_CR0014192","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejpn.2008.06.011","volume":"13","author":"P Vondracek","year":"2009","unstructured":"Vondracek P, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol. 2009;13(4):332\u20136.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"14_CR0014193","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0304-3959(99)00079-2","volume":"83","author":"SH Sindrup","year":"1999","unstructured":"Sindrup SH, et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain. 1999;83(1):85\u201390.","journal-title":"Pain"},{"issue":"6933","key":"14_CR0014194","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/bmj.308.6933.891","volume":"308","author":"M Nordstrom","year":"1994","unstructured":"Nordstrom M, et al. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ. 1994;308(6933):891\u20134.","journal-title":"BMJ"},{"issue":"2","key":"14_CR0014195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF02981929","volume":"73","author":"A Falanga","year":"2001","unstructured":"Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol. 2001;73(2):137\u201344.","journal-title":"Int J Hematol"},{"issue":"1","key":"14_CR0014196","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<180::AID-CNCR24>3.0.CO;2-S","volume":"83","author":"RJ Hettiarachchi","year":"1998","unstructured":"Hettiarachchi RJ, et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer. 1998;83(1):180\u20135.","journal-title":"Cancer"},{"issue":"9","key":"14_CR0014197","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","volume":"112","author":"SY Kristinsson","year":"2008","unstructured":"Kristinsson SY, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9): 3582\u20136.","journal-title":"Blood"},{"issue":"10","key":"14_CR0014198","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ejca.2010.03.007","volume":"46","author":"N Uaprasert","year":"2010","unstructured":"Uaprasert N, et al. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. Eur J Cancer. 2010;46(10):1790\u20139.","journal-title":"Eur J Cancer"},{"issue":"9","key":"14_CR0014199","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00277-004-0891-6","volume":"83","author":"A Corso","year":"2004","unstructured":"Corso A, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol. 2004;83(9):588\u201391.","journal-title":"Ann Hematol"},{"issue":"1","key":"14_CR0014200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","volume":"22","author":"F Elice","year":"2009","unstructured":"Elice F, et al. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 2009;22(1):115\u201328.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"14_CR0014201","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","volume":"100","author":"M Cavo","year":"2002","unstructured":"Cavo M, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood. 2002;100(6): 2272\u20133.","journal-title":"Blood"},{"issue":"10","key":"14_CR0014202","first-page":"1108","volume":"86","author":"L Camba","year":"2001","unstructured":"Camba L, et al. Thalidomide and thrombosis in patients with multiple myeloma. Haematologica. 2001;86(10):1108\u20139.","journal-title":"Haematologica"},{"issue":"7","key":"14_CR0014203","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/cncr.23336","volume":"112","author":"SP Menon","year":"2008","unstructured":"Menon SP, et al. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer. 2008;112(7):1522\u20138.","journal-title":"Cancer"},{"issue":"11","key":"14_CR0014204","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2004.00931.x","volume":"2","author":"C Rus","year":"2004","unstructured":"Rus C, et al. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J Thromb Haemost. 2004;2(11):2063\u20135.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"14_CR0014205","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","volume":"9","author":"M Carrier","year":"2011","unstructured":"Carrier M, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011;9(4):653\u201363.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"14_CR0014206","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414\u201323.","journal-title":"Leukemia"},{"issue":"11","key":"14_CR0014207","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","volume":"121","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121(11): 1961\u20137.","journal-title":"Blood"},{"issue":"16","key":"14_CR0014208","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","volume":"22","author":"SA Schey","year":"2004","unstructured":"Schey SA, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269\u201376.","journal-title":"J Clin Oncol"},{"issue":"11","key":"14_CR0014209","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1080\/10428190600799631","volume":"47","author":"KC Miller","year":"2006","unstructured":"Miller KC, et al. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma. 2006;47(11):2339\u201343.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"14_CR0014210","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","volume":"126","author":"M Zangari","year":"2004","unstructured":"Zangari M, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004;126(5): 715\u201321.","journal-title":"Br J Haematol"},{"issue":"12","key":"14_CR0014211","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","volume":"80","author":"R Baz","year":"2005","unstructured":"Baz R, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80(12):1568\u201374.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"14_CR0014212","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","volume":"108","author":"JA Zonder","year":"2006","unstructured":"Zonder JA, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006;108(1):403; author reply 404.","journal-title":"Blood"},{"issue":"12","key":"14_CR0014213","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","volume":"18","author":"MC Minnema","year":"2004","unstructured":"Minnema MC, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004;18(12):2044\u20136.","journal-title":"Leukemia"},{"issue":"8","key":"14_CR0014214","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","volume":"29","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011; 29(8):986\u201393.","journal-title":"J Clin Oncol"},{"issue":"4","key":"14_CR0014215","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","volume":"119","author":"A Larocca","year":"2012","unstructured":"Larocca A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933\u20139; quiz 1093.","journal-title":"Blood"},{"key":"14_CR0014216","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-4-11","volume":"4","author":"VH Jimenez-Zepeda","year":"2006","unstructured":"Jimenez-Zepeda VH, Dominguez-Martinez VJ. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J. 2006;4:11.","journal-title":"Thromb J"}],"container-title":["Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4614-8520-9_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T17:10:46Z","timestamp":1676826646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-4614-8520-9_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,4]]},"ISBN":["9781461485193","9781461485209"],"references-count":216,"URL":"https:\/\/doi.org\/10.1007\/978-1-4614-8520-9_14","relation":{},"subject":[],"published":{"date-parts":[[2013,9,4]]},"assertion":[{"value":"4 September 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}